BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 28263021)

  • 1. The importance of treating the field in actinic keratosis.
    Stockfleth E
    J Eur Acad Dermatol Venereol; 2017 Mar; 31 Suppl 2():8-11. PubMed ID: 28263021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment considerations in actinic keratosis.
    Goldenberg G
    J Eur Acad Dermatol Venereol; 2017 Mar; 31 Suppl 2():12-16. PubMed ID: 28263018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of patient-centred care to overcome barriers in the management of actinic keratosis.
    Cerio R
    J Eur Acad Dermatol Venereol; 2017 Mar; 31 Suppl 2():17-20. PubMed ID: 28263022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review.
    Jetter N; Chandan N; Wang S; Tsoukas M
    Am J Clin Dermatol; 2018 Aug; 19(4):543-557. PubMed ID: 29582369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.
    Ruini C; Hartmann D; Bastian M; Ruzicka T; French LE; Berking C; von Braunmühl T
    J Biophotonics; 2019 Jul; 12(7):e201800391. PubMed ID: 30653833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Field cancerization: from molecular basis to selective field-directed management of actinic keratosis.
    Philipp-Dormston WG
    Curr Probl Dermatol; 2015; 46():115-21. PubMed ID: 25561215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid.
    Ulrich M; Pellacani G; Ferrandiz C; Lear JT
    Eur J Dermatol; 2014; 24(2):158-67. PubMed ID: 24721544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The paradigm shift in treating actinic keratosis: a comprehensive strategy.
    Stockfleth E
    J Drugs Dermatol; 2012 Dec; 11(12):1462-7. PubMed ID: 23377517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
    Stockfleth E; Bastian M
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of topical interventions for the treatment of actinic keratosis.
    Koch EAT; Wessely A; Steeb T; Berking C; Heppt MV
    Expert Opin Drug Saf; 2021 Jul; 20(7):801-814. PubMed ID: 33834933
    [No Abstract]   [Full Text] [Related]  

  • 11. Actinic keratosis and squamous cell carcinoma: clinical and pathological features.
    Filosa A; Filosa G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):379-84. PubMed ID: 26099352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ingenol mebutate-mediated reduction in p53-positive keratinocytes in skin cancerization field directly correlates with clinical response in patients with multiple actinic keratoses.
    Grandi V; di Gennaro P; Torrigiani S; Basco L; Lastrucci I; Pimpinelli N
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1297-1303. PubMed ID: 30801837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
    Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of actinic keratosis: an update.
    Berman B; Amini S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1847-71. PubMed ID: 22888917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer.
    Puviani M; Barcella A; Milani M
    G Ital Dermatol Venereol; 2013 Dec; 148(6):693-8. PubMed ID: 24442053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo reflectance confocal microscopy characterization of field-directed 5-fluorouracil 0.5%/salicylic acid 10% in actinic keratosis.
    Ulrich M; Alarcon I; Malvehy J; Puig S
    Dermatology; 2015; 230(3):193-8. PubMed ID: 25721522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actinic keratosis: a cross-sectional study of disease characteristics and treatment patterns in Danish dermatology clinics.
    Erlendsson AM; Egekvist H; Lorentzen HF; Philipsen PA; Stausbøl-Grøn B; Stender IM; Haedersdal M
    Int J Dermatol; 2016 Mar; 55(3):309-16. PubMed ID: 26276415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical findings using ingenol mebutate gel to treat actinic keratoses.
    Martin G; Swanson N
    J Am Acad Dermatol; 2013 Jan; 68(1 Suppl 1):S39-48. PubMed ID: 23228305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and current preventive treatment options in actinic keratosis.
    Arenberger P; Arenbergerova M
    J Eur Acad Dermatol Venereol; 2017 Sep; 31 Suppl 5():13-17. PubMed ID: 28805940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical management of actinic keratosis and field cancerisation.
    Stockfleth E
    G Ital Dermatol Venereol; 2009 Aug; 144(4):459-62. PubMed ID: 19755950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.